Shares of Aerie Pharmaceuticals Inc (NASDAQ:AERI) have received an average rating of “Buy” from the seventeen research firms that are covering the firm, Marketbeat reports. Four investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. The average 1 year target price among analysts that have covered the stock in the last year is $71.77.
Several brokerages have commented on AERI. Guggenheim began coverage on Aerie Pharmaceuticals in a research note on Monday, October 23rd. They set a “buy” rating and a $80.00 target price for the company. BidaskClub raised Aerie Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Tuesday, December 5th. Zacks Investment Research downgraded Aerie Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, February 2nd. Mizuho reissued a “buy” rating and set a $87.00 target price on shares of Aerie Pharmaceuticals in a research note on Tuesday, December 19th. Finally, Canaccord Genuity set a $73.00 target price on Aerie Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, November 16th.
Hedge funds have recently made changes to their positions in the stock. QS Investors LLC bought a new stake in Aerie Pharmaceuticals in the fourth quarter valued at approximately $125,000. Ameritas Investment Partners Inc. boosted its holdings in Aerie Pharmaceuticals by 11.5% in the second quarter. Ameritas Investment Partners Inc. now owns 2,665 shares of the company’s stock valued at $140,000 after acquiring an additional 275 shares during the last quarter. Quantbot Technologies LP boosted its holdings in Aerie Pharmaceuticals by 792.5% in the third quarter. Quantbot Technologies LP now owns 2,981 shares of the company’s stock valued at $144,000 after acquiring an additional 2,647 shares during the last quarter. Public Employees Retirement Association of Colorado bought a new stake in Aerie Pharmaceuticals in the fourth quarter valued at approximately $176,000. Finally, Amalgamated Bank bought a new stake in Aerie Pharmaceuticals in the second quarter valued at approximately $204,000. Institutional investors and hedge funds own 97.81% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This article was first published by Markets Daily and is owned by of Markets Daily. If you are reading this article on another website, it was illegally stolen and reposted in violation of international trademark & copyright laws. The legal version of this article can be accessed at https://www.themarketsdaily.com/2018/02/15/aerie-pharmaceuticals-inc-aeri-receives-consensus-rating-of-buy-from-analysts.html.
About Aerie Pharmaceuticals
Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).
Receive News & Ratings for Aerie Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.